To me its worth noticing Dr Perry’s Performance targets for...

To me its worth noticing Dr Perry’s Performance targets for incentive share based renumeration set by the Board in the recent AGM document.

Notably:

1. Achieve Centres for Medicare and Medicaid Services reimbursement for out-patient transitional pass through payment code (TPT) by June 30, 2022

2. Achieve Japanese approval from PMDA and reimbursement code by September 30, 2022

3. Achieve profitability of company’s Burns business for 2 consecutive quarters by March 31, 2023

4. Achieve US FDA approval of vitiligo indication by December 31, 2023

5. Achieve a doubling (based on 10-day volume weighted average price) of the company’s share price as of the date of the 2021 AGM by June 30,2023

6. Achieve a market capitalization of greater than or equal to US 1.25 billion and maintain that market capitalization for at least 30 consecutive calendar days before December 31, 2024.

Dr Perry has historically hit his targets. If this continues within 3 years the MC will be 4 times current (market Cap currently just US 320 Million) with burns business profitability (inpatient, outpatient and paediatric), Japanese sales ramping up 2 years after launch and vitiligo sales underway. Sounds pretty appetising to me.

Perhaps that is why the Montgomery fund run by professionals has just bought up 5% of this company.

This product has been held back in its roll out by COVID which hit exactly at the wrong time when momentum was building but the tech is tremendous and will not be held back for too much longer IMO.

Remember Avita has a monopoly on the autologous skin spray space (with patents to boot) and this tech is fast becoming the new SOC in burn/trauma centres in the US which the world standard for medical care.

Patience will be rewarded IMO.